• Explore /
  • Poster
  • / Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).

Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).

Abstract Poster

Authors

Hagop Kantarjian

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center, Houston, TX

Hagop M. Kantarjian , Javier Pinilla-Ibarz , Philipp D. Le Coutre , Ronald Paquette , Charles Chuah , Franck E. Nicolini , Jane Apperley , Hanna Jean Khoury , Moshe Talpaz , Michele Baccarani , Stephanie Lustgarten , Sergio Santillana , Francois Guilhot , Michael W.N. Deininger , Andreas Hochhaus , Timothy P. Hughes , Neil P. Shah , Jorge E. Cortes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Chronic Leukemia—CML

Clinical Trial Registration Number

NCT01207440

Citation

J Clin Oncol 35, 2017 (suppl; abstr 7012)

DOI

10.1200/JCO.2017.35.15_suppl.7012

Abstract #

7012

Poster Bd #

212

Abstract Disclosures

Similar Posters

Poster

2016 ASCO Annual Meeting

4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.

4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.

First Author: Jorge E. Cortes

First Author: Michael C. Heinrich

First Author: Hagop M. Kantarjian

First Author: Belal Firwana